September 15, 2016: This trial has been completed. Please stay in touch for information about future trials.

August 17, 2015: Retrotope, Inc. is currently conducting

A Randomized, Double-Blind, Controlled Study to Assess the Safety, Tolerability, and Pharmacokenetics of RT001 in Patients With Friedreich’s Ataxia”.

You can read a press release about this trial by clicking here.

If you are interested in learning more about this study please visit Clinicaltrials.gov here.

or contact us at: clinicaltrials@retrotope.com